Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) announced upcoming presentations at investor conferences. Kevin Gorman, CEO, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 a.m. ET. On November 17, 2020, at 9:40 a.m. ET, Gorman and CFO Matt Abernethy will present at the Jefferies Virtual London Healthcare Conference. Both presentations will be available via webcast on Neurocrine's website, with replays accessible for one month.

Neurocrine focuses on developing treatments for neurological and endocrine disorders.

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:

• Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Stifel 2020 Virtual Healthcare Conference at 11:20 a.m. Eastern Time on Monday, November 16, 2020.
• Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Jefferies Virtual London Healthcare Conference at 2:40 p.m. Greenwich Mean Time (9:40 a.m. Eastern Time) on Tuesday, November 17, 2020.

The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301168288.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What events will Neurocrine Biosciences participate in on November 16 and 17, 2020?

Neurocrine Biosciences will present at the Stifel 2020 Virtual Healthcare Conference on November 16 at 11:20 a.m. ET and at the Jefferies Virtual London Healthcare Conference on November 17 at 9:40 a.m. ET.

Who are the presenters from Neurocrine Biosciences at the upcoming conferences?

Kevin Gorman, CEO, Kyle Gano, Chief Business Development and Strategy Officer, and Matt Abernethy, CFO, will present at the conferences.

Where can I watch the Neurocrine Biosciences presentations?

The presentations will be webcast and accessible on the Neurocrine Biosciences website under the Investors section.

Will there be a replay of the Neurocrine presentations?

Yes, a replay of the presentations will be available approximately one hour after the events and archived for about one month.

What is Neurocrine Biosciences focused on?

Neurocrine Biosciences is focused on discovering, developing, and delivering treatments for neurological, endocrine, and psychiatric disorders.